168 related articles for article (PubMed ID: 22217982)
1. Cytokine modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis.
Giordano N; Papakostas P; Pecetti G; Nuti R
J Biol Regul Homeost Agents; 2011; 25(4):487-92. PubMed ID: 22217982
[TBL] [Abstract][Full Text] [Related]
2. Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings.
Corallo C; Pecetti G; Iglarz M; Volpi N; Franci D; Montella A; D' Onofrio F; Nuti R; Giordano N
J Biol Regul Homeost Agents; 2013; 27(2):455-62. PubMed ID: 23830395
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
Shiwen X; Leask A; Abraham DJ; Fonseca C
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor antagonism--new perspectives in the treatment of systemic sclerosis.
Kowal-Bielecka O; Sierakowski S
Rocz Akad Med Bialymst; 2005; 50 Suppl 1():291-3. PubMed ID: 16119689
[TBL] [Abstract][Full Text] [Related]
5. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis.
Baraut J; Michel L; Verrecchia F; Farge D
Autoimmun Rev; 2010 Dec; 10(2):65-73. PubMed ID: 20713187
[TBL] [Abstract][Full Text] [Related]
6. B cells in systemic sclerosis: a possible target for therapy.
Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
[TBL] [Abstract][Full Text] [Related]
7. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients.
Manetti M; Neumann E; Milia AF; Tarner IH; Bechi P; Matucci-Cerinic M; Ibba-Manneschi L; Müller-Ladner U
Arthritis Rheum; 2007 Oct; 56(10):3442-7. PubMed ID: 17907149
[TBL] [Abstract][Full Text] [Related]
8. [Vascular manifestations in systemic sclerosis (scleroderma)].
Cafagna D; Melon F; Balbi M; Ponte E
Minerva Med; 1998 May; 89(5):153-61. PubMed ID: 9676180
[TBL] [Abstract][Full Text] [Related]
9. T cell abnormalities in systemic sclerosis with a focus on Th17 cells.
Brembilla NC; Chizzolini C
Eur Cytokine Netw; 2012; 23(4):128-39. PubMed ID: 23360781
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP; Black CM; Abraham DJ
Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
[TBL] [Abstract][Full Text] [Related]
11. [Immunopathological disturbances in systemic sclerosis].
Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
[TBL] [Abstract][Full Text] [Related]
12. Immunological basis of systemic sclerosis.
Zuber JP; Spertini F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii23-5. PubMed ID: 16987826
[TBL] [Abstract][Full Text] [Related]
13. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
Sulli A; Soldano S; Pizzorni C; Montagna P; Secchi ME; Villaggio B; Seriolo B; Brizzolara R; Cutolo M
J Rheumatol; 2009 Jun; 36(6):1235-9. PubMed ID: 19369451
[TBL] [Abstract][Full Text] [Related]
14. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis.
Leask A
Pharmacol Res; 2011 Jun; 63(6):502-3. PubMed ID: 21315153
[TBL] [Abstract][Full Text] [Related]
15. [Physiopathology of scleroderma].
Fleischmajer R; Perlish JS; Maquart FX; Kalis B
Ann Dermatol Venereol; 1993; 120(2):157-66. PubMed ID: 8363310
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis.
Bellisai F; Morozzi G; Scaccia F; Chellini F; Simpatico A; Pecetti G; Galeazzi M
Int J Immunopathol Pharmacol; 2011; 24(1):261-4. PubMed ID: 21496413
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of scleroderma: an update.
Haustein UF; Anderegg U
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):1-8. PubMed ID: 9731958
[TBL] [Abstract][Full Text] [Related]
18. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis.
Rajkumar VS; Sundberg C; Abraham DJ; Rubin K; Black CM
Arthritis Rheum; 1999 May; 42(5):930-41. PubMed ID: 10323448
[TBL] [Abstract][Full Text] [Related]
19. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
[TBL] [Abstract][Full Text] [Related]
20. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?
Vancheeswaran R; Magoulas T; Efrat G; Wheeler-Jones C; Olsen I; Penny R; Black CM
J Rheumatol; 1994 Oct; 21(10):1838-44. PubMed ID: 7837147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
